Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Wegovy, a weight loss drug made famous by celebrities around the world, is on New Zealand pharmacists' shelves, but it is ...

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.

The weight loss and diabetes drug Wegovy (also known as Ozempic) which is only available on prescription, should be on pharmacy shelves as of 1 July, drug maker Novo Nordisk confirmed. It ends a years ...

This month, the Danish prime minister Mette Frederiksen takes up her presidency of the EU – and the timing could not be more ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...